雷诺嗪通过调节脑源性神经营养因子和脑线粒体tu翻译延伸因子(TUFM)对大脑中动脉闭塞/再灌注缺血性损伤的神经保护作用。

IF 3.5 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Mohammad Aquib Siddiqui, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy
{"title":"雷诺嗪通过调节脑源性神经营养因子和脑线粒体tu翻译延伸因子(TUFM)对大脑中动脉闭塞/再灌注缺血性损伤的神经保护作用。","authors":"Mohammad Aquib Siddiqui, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy","doi":"10.1007/s11011-025-01708-5","DOIUrl":null,"url":null,"abstract":"<p><p>The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.</p>","PeriodicalId":18685,"journal":{"name":"Metabolic brain disease","volume":"40 7","pages":"285"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ranolazine neuroprotection against middle cerebral artery occlusion/reperfusion ischemic injury via modulation of brain-derived neurotrophic factor and brain mitochondrial tu translation elongation factor (TUFM).\",\"authors\":\"Mohammad Aquib Siddiqui, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy\",\"doi\":\"10.1007/s11011-025-01708-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.</p>\",\"PeriodicalId\":18685,\"journal\":{\"name\":\"Metabolic brain disease\",\"volume\":\"40 7\",\"pages\":\"285\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Metabolic brain disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11011-025-01708-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic brain disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11011-025-01708-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

本研究探讨雷诺嗪在缺血性脑卒中中的治疗潜力,重点研究其对大鼠大脑中动脉闭塞/再灌注(MCAO/R)缺血性脑损伤模型的神经保护作用。雷诺嗪通过减少梗死面积和脑水肿,改善脑血流量,保持血脑屏障完整性,从而改善神经功能,显示出神经保护作用。机制上,雷诺嗪降低HIF-1α和GFAP表达,同时提高BDNF水平。雷诺嗪提高了线粒体复合体酶(I、II、IV和V)活性,提高了线粒体Tu翻译延伸因子(TUFM)、NRF1和PGC-1α的表达水平,表明线粒体生物发生改善,线粒体氧化应激标志物(如4-HNE)降低,过氧化氢酶和SOD升高。此外,雷诺嗪治疗降低了促炎细胞因子TNF-α和IL-6的水平,同时增加了抗炎细胞因子IL-10的水平,表明其在缓解卒中相关神经炎症方面具有抗炎潜力。此外,雷诺嗪通过降低细胞色素c、caspase-9、caspase-3等凋亡介质的水平抑制细胞凋亡,流式细胞术分析显示神经元凋亡明显下降,进一步强调了其神经保护作用。因此,本研究的新颖之处在于,证明雷诺嗪通过同时调节凋亡通路、恢复重要神经因子(BDNF、TUFM、NRF-1、PGC-1α)、改善线粒体功能、减少氧化应激、减轻神经炎症,对缺血性脑损伤发挥神经保护作用,提供了一种新的多靶点治疗方法,值得进一步的临床研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ranolazine neuroprotection against middle cerebral artery occlusion/reperfusion ischemic injury via modulation of brain-derived neurotrophic factor and brain mitochondrial tu translation elongation factor (TUFM).

The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Metabolic brain disease
Metabolic brain disease 医学-内分泌学与代谢
CiteScore
5.90
自引率
5.60%
发文量
248
审稿时长
6-12 weeks
期刊介绍: Metabolic Brain Disease serves as a forum for the publication of outstanding basic and clinical papers on all metabolic brain disease, including both human and animal studies. The journal publishes papers on the fundamental pathogenesis of these disorders and on related experimental and clinical techniques and methodologies. Metabolic Brain Disease is directed to physicians, neuroscientists, internists, psychiatrists, neurologists, pathologists, and others involved in the research and treatment of a broad range of metabolic brain disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信